1. Volume 385, Issue 9977, Pages 1545-1554 (April 2015)
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial 
Hannah Kibuuka, MMed, Nina M Berkowitz, MPH, Monica Millard, MPH, Mary E Enama, MA, Allan Tindikahwa, MPH, Arthur B Sekiziyivu, MSc, Pamela Costner, BSN, Sandra Sitar, MS, Deline Glover, BS, Zonghui Hu, PhD, Gyan Joshi, MPH, Daphne Stanley, MS, Meghan Kunchai, MPH, Leigh Anne Eller, PhD, Robert T Bailer, PhD, Richard A Koup, MD, Gary J Nabel, MD, John R Mascola, MD, Nancy J Sullivan, PhD, Barney S Graham, MD, Mario Roederer, PhD, Nelson L Michael, MD, Merlin L Robb, MD, Dr Julie E Ledgerwood, DO 
The Lancet 
Volume 385, Issue 9977, Pages (April 2015)
DOI: /S (14)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
CD4 T-cell responses to all antigens assessed by intracellular cytokine staining
(A) Median CD4 responses (error bars show IQRs). Responses reached near maximum levels at week 12 (4 weeks after the third vaccination) and persisted for about 1 year. Week 8 is the time of the third vaccination, so the response at that timepoint is after two injections. Only significant p values (p<0·05) are shown. (B) Median CD4 responses by antigen at 4 weeks after the third vaccination. Responses were not cross-reactive between EBO and MAR vaccine groups. Only significant p values (p<0·05) are shown. (C) Qualitative profiles of antigen-specific polyfunctional memory T-cell responses are shown by cytokine at week 12. Data are shown if more than five individuals can be averaged and are only shown for positive responders (n is the number of positive responders).
The Lancet  , DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions